Vuja De Sciences - About the company
Vuja De Sciences is a seed company based in Hoboken (United States), founded in 2017 by Raphael Nir, Richard Lampe, Robert Hurst and David Warshawsky. It operates as a Developer of therapies for preventing metastasis and recurrence of cancers. Vuja De Sciences has raised $3.94M in funding. The company has 110 active competitors, including 25 funded and 27 that have exited. Its top competitors include companies like argenx, Vor Biopharma and Radius Health.
Company Details
Developer of therapies for preventing metastasis and recurrence of cancers. It offers a lead candidate VUJ-100 that has anti metastatic activity based on properitory platform for multiple metastatic osteosarcoma and other cancer models.
- Website
- vujade-life.com
- Email ID
- *****@vujade-life.com
Key Metrics
Founded Year
2017
Location
Hoboken, United States
Stage
Seed
Total Funding
$3.94M in 10 rounds
Latest Funding Round
Ranked
9th among 110 active competitors
Employee Count
2 as on Aug 31, 2026
Legal entities associated with Vuja De Sciences
Vuja De Sciences is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Vuja De Sciences, Inc. CIN: 822445024 , United States, Active | Dec 31, 2016 | - | - | - |
Sign up to download Vuja De Sciences' company profile
Vuja De Sciences's funding and investors
Vuja De Sciences has raised a total funding of $3.94M over 10 rounds. Its first funding round was on May 20, 2019.
Here is the list of recent funding rounds of Vuja De Sciences:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Oct 04, 2024 | 2213532 | Conventional Debt | 3214910 | 5984342 | 3791937 | 8774244 |
Oct 04, 2024 | 3141333 | Seed | 3264158 | 3528085 | 2545218 | 1704660 |
Feb 06, 2024 | 8943534 | Seed | 9901023 | 1704705 | 3893242 | 2403811 |
View details of Vuja De Sciences's funding rounds and investors
Vuja De Sciences' founders and board of directors
Founder? Claim ProfileHere are the details of Vuja De Sciences' key team members:
- Raphael Nir: Co-Founder of Vuja De Sciences.
- Richard Lampe: Co-Founder of Vuja De Sciences.
- Robert Hurst: Co-Founder of Vuja De Sciences.
- David Warshawsky: Co-Founder of Vuja De Sciences.
View details of Vuja De Sciences's Founder profiles and Board Members
Vuja De Sciences' employee count trend
Vuja De Sciences has 2 employees as of Aug 26. Here is Vuja De Sciences's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Vuja De Sciences's Competitors and alternates
Top competitors of Vuja De Sciences include argenx, Vor Biopharma and Radius Health. Here is the list of Top 10 competitors of Vuja De Sciences, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 75/100 | ||
2nd | Vor Biopharma 2019, Cambridge (United States), Public | Developer of therapeutics to treat acute myeloid leukemia | $152M | 68/100 | |
3rd | Radius Health 2003, Boston (United States), Acquired | Biopharmaceutical company focused on bone health and related therapeutic areas | $213M | 63/100 | |
4th | Healx 2014, Cambridge (United Kingdom), Series C | Provider of AI-powered drug discovery solutions for rare diseases | $115M | 62/100 | |
5th | Horizon Therapeutics 2008, Dublin (Ireland), Acquired | Developer of drugs for treating rare and autoimmune diseases | $61.8M | 61/100 | |
6th | Quince Therapeutics 2012, San Francisco (United States), Public | Developer of therapeutics for orthopedic diseases | $108M | 60/100 | |
7th | Angitia 2018, Woodland Hills (United States), Series D | Developer of drugs for muscle, bone, and joint diseases | $406M | 58/100 | |
8th | Alesta Therapeutics 2021, Leiden (Netherlands), Acquired | Developer of small molecule therapies for rare diseases | $67.5M | 56/100 | |
9th | Vuja De Sciences 2017, Hoboken (United States), Seed | Developer of therapies for preventing metastasis and recurrence of cancers | $3.94M | - | 55/100 |
10th | Valitor 2010, Berkeley (United States), Series B | Developer of therapeutic proteins for multiple disease conditions | $38.2M | 55/100 |
Looking for more details on Vuja De Sciences's competitors? Click here to see the top ones
Vuja De Sciences's Investments and acquisitions
Vuja De Sciences has made no investments or acquisitions yet.
Reports related to Vuja De Sciences
Here is the latest report on Vuja De Sciences's sector:
News related to Vuja De Sciences
•
Healx Focuses on Cancer Recurrence Prevention via Vuja De Sciences TransactionBusiness Wire•Sep 23, 2025•Healx, Vuja De Sciences
•
Vuja De Sciences has filed a notice of an exempt offering of securities to raise $1,000,000.00 in New Equity and Debt Financing.intelligence360•Jun 10, 2024•Vuja De Sciences
•
HebeCell and Vuja De Sciences Announce Strategic CollaborationPRWeb•Apr 06, 2022•HebeCell, Vuja De Sciences
•
Cyclenium Pharma and Vuja De Sciences Announce Oncology Drug Discovery CollaborationBusiness Wire•Jan 05, 2022•Cyclenium Pharma, Vuja De Sciences
•
Vuja De Sciences Announces the Appointment of Two New Board MembersPRWeb•Jan 07, 2020•Vuja De Sciences, Ethos Vet Health
Are you a Founder ?
FAQs about Vuja De Sciences
Explore our recently published companies
- Alexander Construction - Houston based, Unfunded company
- Rnbcorp - Unfunded company
- SeekAdvantage - Unfunded company
- Ice Guy Consulting - Unfunded company
- Ly Advisory - Unfunded company
- Leo-Ag - Unfunded company
_1558432141609.webp?format=webp&height=120&width=120)